ClinicalTrials.gg
RecruitingNCT06344091Updated Sep 28, 2026

A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients

A Phase 4 interventional study of Bupivacaine Liposome Injection in Local Analgesia Via Infiltration, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Sep 28, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
232
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the safety and efficacy of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgery in the real world.

02

Conditions studied

  • Local Analgesia Via Infiltration
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects and guardians are willing to sign the .
  2. Subjects undergoing orthopedic surgery under general anesthesia with expected cumulative incision length ≥ 3cm.
  3. 6 years old ≤ age ≤ 17 years old, Male or female.
  4. ASA Physical Status Classification I-III.

Exclusion criteria

Exclusion Criteria:

  1. Subjects received liposomal bupivacaine or bupivacaine hydrochloride within the past 30 days.
  2. Subjects with a history of immunodeficiency diseases (such as congenital immunodeficiency disease, AIDS or malignant tumors) or received within 30 days.
  3. Subjects with comorbid mental diseases (such as schizophrenia, depression, etc.) or difficult to communicate.
  4. Subjects with a history of chronic pain or visceral pain.
  5. Subjects with abnormal liver and kidney function.
  6. Subjects with abnormal heart rate or rhythm.
  7. Subjects who are participating or planning to participate in any interventional clinical trial.
  8. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    Bupivacaine Liposome Injection

    Drug: Bupivacaine Liposome Injection

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of Treatment Emergent Adverse events (TEAE) in the cardiac and nervous system

    Proportion of patients with any TEAE of cardiac or nervous system in MedDRA (Medical Dictionary for Regulatory Activities).

    Time frame: 0 minute to 14 days after administration

Secondary outcomes

  1. The cumulative amount of opioids used in 0-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after administration

    Total consumption of opioids during 0-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after administration.

    Time frame: 0 minute to 72 hours after administration

  2. Time to first rescue analgesia of opioid

    Duration from administration to first use of opioid for rescue analgesia.

    Time frame: 0 minute to 72 hours after administration

  3. The proportion of patients who did not use rescue analgesia during 0-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after administration

    The proportion of patients who did not use rescue analgesia during 72 hours after administration.

    Time frame: 0 minute to 72 hours after administration

  4. The proportion of patients using patient-controlled intravenous analgesia (PCIA)

    The proportion of patients who used patient-controlled intravenous analgesia (PCIA) during 0-72 hours after administration.

    Time frame: 0 minute to 72 hours after administration

  5. Pain intensity score at rest after administration for children aged 6 to 7 years

    Wong Baker Faces Pain Scale Revision (FPS-R,0 indicates no pain and 10 indicates the most severe pain) was used for children aged 6 to 7 years at the time of 30minutes after awakening (including 30minutes), 6hours (±30minutes), 12hours (±30minutes), 18hours (±30minutes), 24hours (±30minutes), 36hours (±30minutes), 48hours (±30minutes) and 72hours (±30minutes).

    Time frame: 0 minute to 72 hours after administration

  6. Pain intensity score at rest after administration for children aged 8 years and older

    Numerical Rating Scale (0 indicates no pain and 10 indicates the most severe pain) was used for children aged 8 years and older to assess the intensity of pain at the time of 30minutes after awakening (including 30minutes), 6hours (±30minutes), 12hours (±30minutes), 18hours (±30minutes), 24hours (±30minutes), 36hours (±30minutes), 48hours (±30minutes) and 72hours (±30minutes).

    Time frame: 0 minute to 72 hours after administration

  7. Pain intensity score on movement (or cough) after administration for children aged 6 to 7 years

    Wong Baker Faces Pain Scale Revision (FPS-R,0 indicates no pain and 10 indicates the most severe pain) was used for children aged 6 to 7 years at the time of 30minutes after awakening (including 30minutes), 6hours (±30minutes), 12hours (±30minutes), 18hours (±30minutes), 24hours (±30minutes), 36hours (±30minutes), 48hours (±30minutes) and 72hours (±30minutes).

    Time frame: 0 minute to 72 hours after administration

  8. Pain intensity score on movement (or cough) after administration for children aged 8 years and older

    Numerical Rating Scale (0 indicates no pain and 10 indicates the most severe pain) was used for children aged 8 years and older to assess the intensity of pain at the time of 30minutes after awakening (including 30minutes), 6hours (±30minutes), 12hours (±30minutes), 18hours (±30minutes), 24hours (±30minutes), 36hours (±30minutes), 48hours (±30minutes) and 72hours (±30minutes).

    Time frame: 0 minute to 72 hours after administration

  9. Length of Stay

    The score of Post-Anesthetic Discharge Scoring System Scale (PADSS) was used to determine whether the patient could be discharged.

    Time frame: Up to 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2026 → May 2027 and completion Oct 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Apr 3, 2024
StartActual
May 21, 2024
Primary completionEst.
May 2027was Sep 2026
CompletionEst.
May 2027was Oct 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 28, 2026→May 2027
Sep 28, 2026
Study completion
Oct 12, 2026→May 2027
Sep 28, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionThe incidence of Treatment Emergent Adverse events (TEAE) in the cardiac and nervous system: how it is measured was reworded
Sep 28, 2026
Secondary outcomes
1 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameLength of Stayup to 2 weeks → Up to 2 weeks
  • DescriptionPain intensity score at rest after administration for children aged 8 years and older: how it is measured was reworded
  • DescriptionPain intensity score on movement (or cough) after administration for children aged 8 years and older: how it is measured was reworded
Sep 28, 2026
Contact
Study contact's phone or email changed: •••2973→•••2973. See the current contact
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Guangzhou Women and Children's Medical Center · Guangzhou, ChinaContact none listed→s•••@126.comContact added (no phone or email listed)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Sep 28, 2026→May 2027
    Study completion Oct 12, 2026→May 2027
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionThe incidence of Treatment Emergent Adverse events (TEAE) in the cardiac and nervous system: how it is measured was reworded
    Secondary outcomes 1 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameLength of Stayup to 2 weeks → Up to 2 weeks
    • DescriptionPain intensity score at rest after administration for children aged 8 years and older: how it is measured was reworded
    • DescriptionPain intensity score on movement (or cough) after administration for children aged 8 years and older: how it is measured was reworded
    Contact Study contact's phone or email changed: •••2973→•••2973. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Guangzhou Women and Children's Medical Center · Guangzhou, ChinaContact none listed→s•••@126.comContact added (no phone or email listed)
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06344091
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
May 21, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Thea Yu
Contact
suyang.yu.sy17@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion